Metabolic Changes in the Activated Human Visual Cortex During Mild Hypoxia

The primary objective of this research is to measure changes in neurochemical concentrations during stimulation of the primary visual cortex, in both conditions of normoxia (normal oxygen availability) and induced mild hypoxia (reduced oxygen availability).

Study Overview

• Status: Completed
• Conditions: Brain Hypoxia
• Intervention / Treatment: Device: Mild Hypoxia

Detailed Description

The goal is to determine the effect of mild hypoxia on human brain energy metabolism of healthy young adult subjects. For this purpose, the Investigator will utilize non-invasive imaging modalities based on functional magnetic resonance spectroscopy (fMRS) to estimate metabolic changes during a visual stimulus, while subjects are exposed to well-controlled gas mixtures that resembles conditions of either normoxia or mild hypoxia. Identifying the impact of mild hypoxia on functional brain energy metabolism in the healthy human brain is a crucial step for generating hypotheses in multiple patient populations that experience mild hypoxia as consequence of their pathological condition, such as in sleep apnea and traumatic brain injury. The Investigator hypothesize that the energetic demands of neuronal activation as revealed by fMRS will not be affected by mild hypoxia.

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Center for Magnetic Resoance Research, University of Minnesota

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Those volunteers who are evaluated as normal and not met exclusion criteria will be potential candidates for this study.

Exclusion Criteria:

• Subjects with any type of bio-implant activated by mechanical, electronic, or magnetic means (e.g. cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.).
• Subjects with any type of ferromagnetic bio-implant that could potentially be displaced or damaged, such as aneurysm clips, metallic skull plates, etc.
• Females.
• Subjects that exhibit noticeable anxiety and/or claustrophobia.
• Subjects who cannot adhere to the experimental protocol for any reason.
• Subjects who have cardiac or known circulatory impairment, and/or the inability to perspire (poor thermoregulatory function).
• Subjects who have known conditions which can lead to emergency medical care.
• Been diagnosed by a physician as having a psychiatric disorder, substance abuse, neurological, cardiovascular.
• Been diagnosed by a physician as having respiratory diseases.
• Had a brain tumor or stroke.
• Started taking chemotherapy or immunomodulatory agents, or had any radiation treatment that could affect the brain.
• Had two or more seizures, or been given a diagnosis of epilepsy.
• Gotten a non-removable piercing or permanent eyeliner.
• Had a head injury that caused you to lose consciousness for more than 30 minutes or have amnesia for more than 24 hours.
• Anyone with a history of sleep apnea or head trauma that may have caused Traumatic Brain Injury (TBI).
• Gotten some type of metal in your body, either from a medical procedure or an injury.
• Male subjects with long beard which wouldn't allow a complete seal between the mask and the face.
• Anyone who is not able to see long distance without glasses or contacts.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Mild Hypoxia; Subjects are exposed to an intervention that controls the composition of breathed air by using a gas blender (RespirAct). Subjects undergo MRI and MRS while breathing air with both normal oxygen concentration (normoxia) and reduced oxygen concentration (mild hypoxia).

Device: Mild Hypoxia; During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from ~21% (room air) to ~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Glutamate Concentration During a Visual Stimulus Measured by fMRS at Normoxia	Relative change in glutamate concentration from rest to visual stimulation as measured by fMRS (with water suppression) in the primary visual cortex during conditions of normoxia.	Baseline and Visual Stimulation at 4 minutes
Change in Glutamate Concentration During a Visual Stimulus Measured by Functional MRS at Hypoxia	Relative change in glutamate concentration from rest to visual stimulation as measured by fMRS (with water suppression) in the primary visual cortex during conditions of hypoxia.	Baseline and Visual Stimulation at 4 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Brain Activity Measured by Blood Oxygenation Level Dependent (BOLD) Signal at Normoxia	Relative change in water signal intensity from rest to visual stimulation as measured by fMRS (without water suppression) in the primary visual cortex during conditions of normoxia.	Baseline and Visual Stimulation at 30 seconds
Brain Activity Measured by Blood Oxygenation Level Dependent (BOLD) Signal at Hypoxia	Relative change in water signal intensity from rest to visual stimulation as measured by fMRS (without water suppression) in the primary visual cortex during conditions of hypoxia.	Baseline and Visual Stimulation at 30 seconds

Collaborators and Investigators

• Sponsor: University of Minnesota
• Investigators: Principal Investigator: Silvia Mangia, PhD, University of Minnesota

Publications and helpful links

General Publications

• Ho YC, Vidyasagar R, Shen Y, Balanos GM, Golay X, Kauppinen RA. The BOLD response and vascular reactivity during visual stimulation in the presence of hypoxic hypoxia. Neuroimage. 2008 Jun;41(2):179-88. doi: 10.1016/j.neuroimage.2008.02.048. Epub 2008 Mar 6.
• Tuunanen PI, Murray IJ, Parry NR, Kauppinen RA. Heterogeneous oxygen extraction in the visual cortex during activation in mild hypoxic hypoxia revealed by quantitative functional magnetic resonance imaging. J Cereb Blood Flow Metab. 2006 Feb;26(2):263-73. doi: 10.1038/sj.jcbfm.9600186.

Helpful Links

• Profile of Principle Investigator

Study record dates

Study Major Dates

• Study Start (Actual): August 13, 2015
• Primary Completion (Actual): September 26, 2016
• Study Completion (Actual): September 26, 2016

Study Registration Dates

• First Submitted: June 23, 2015
• First Submitted That Met QC Criteria: June 23, 2015
• First Posted (Estimate): June 26, 2015

Study Record Updates

• Last Update Posted (Actual): March 19, 2019
• Last Update Submitted That Met QC Criteria: March 11, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Keywords: Functional MRS; Glutamate
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Signs and Symptoms, Respiratory; Hypoxia; Hypoxia, Brain
• Other Study ID Numbers: 201503M65382

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No